In this webinar, you will learn:

• Key considerations to select the right lipid excipients
• The process development steps to bring a LNP formulation to GMP manufacturing and clinical trials
• More about our Millipore^® CTDMO services, from mRNA to lipids and LNPs manufacturing

Detailed description:

Covid-19 vaccines have demonstrated the clinical potential of mRNA-Lipid Nanoparticle formulations. To enable the development of next-generation lipid-based drug delivery systems, expertise and manufacturing capabilities are critical.

Relying on more than 20 years experience in GMP lipid/LNP manufacturing, we aim at supporting pioneers in nucleic acid modalities to bring life changing medicines from preclinical to commercial manufacturing.

An on-demand version of this webinar will be available after the live event using the same link. Register now and access the webinar at your convenience.